Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Hong et al.,
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication,
Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43
HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding found, OR 0.111, p=0.001. 57.1% viral clearance with 1-4 days delay vs. 22.9% for 5+ days delayed treatment. Authors report that early administration of HCQ significantly ameliorates inflammatory cytokine secretion and that COVID-19 patients should be administrated HCQ as soon as possible. 42 patients with HCQ 1-4 days from diagnosis, 48 with HCQ 5+ days from diagnosis.
risk of prolonged viral shedding, early vs. late HCQ, 64.9% lower, RR 0.35, p = 0.001, treatment 42, control 48, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Hong et al., 16 Jul 2020, retrospective, South Korea, peer-reviewed, 7 authors, dosage not specified.
Abstract: Infect Chemother. 2020 Sep;52(3):396-402
https://doi.org/10.3947/ic.2020.52.3.396
pISSN 2093-2340·eISSN 2092-6448
Brief Communication
Early Hydroxychloroquine
Administration for Rapid Severe Acute
Respiratory Syndrome Coronavirus 2
Eradication
Kyung Soo Hong
Hong Nam Kim
, Jong Geol Jang 1, Jian Hur 2, Jong Ho Lee
, Wonhwa Lee 5,*, and June Hong Ahn 1,*
1
,
3
4,*
Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam
University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, Korea
2
Division of Infection, Department of Internal Medicine, College of Medicine, Yeungnam University, Yeungnam
University Medical Center, Daegu, Korea
3
Department of Laboratory Medicine, College of Medicine, Yeungnam University, Yeungnam University
Medical Center, Daegu, Korea
4
Center for BioMicrosystems, Brain Science Institute, Korea Institute of Science and Technology (KIST),
Seoul, Korea
5
Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
1
Received: May 23, 2020
Accepted: Jun 29, 2020
Corresponding Author:
Hong Nam Kim, PhD
Center for BioMicrosystems, Brain Science
Institute Korea Institute of Science and
Technology, 5, Hwarang-ro 14 gil, Seongbukgu, Seoul 02792, Korea.
Tel: +82-2-958-5617
Fax:+82-2-958-6910
E-mail: hongnam.kim@kist.re.kr
Wonhwa Lee, PhD
Aging Research Center, Korea Research
Institute of Bioscience and Biotechnology, 125
Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea.
Tel: +82-42-879-8143
Fax: +82-42-879-8596
E-mail: bywonhwalee@gmail.com
ABSTRACT
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak.
We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for
30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95%
confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of
viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates
inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest
that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
Keywords: Early; Hydroxychloroquine; Coronavirus disease 2019; Eradication
*Hong Nam Kim, Wonhwa Lee, and June Hong
Ahn corresponded equally to the work.
Coronavirus disease 2019 (COVID-19) pneumonia outbreak, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan, China in
December 2019, rapidly spread to produce a worldwide pandemic [1]. There are no proven
therapeutics for COVID-19, and current toll estimate more than 2.7 million infected people
and almost 200 thousand deaths worldwide as of April 24 2020, according to data compiled
by Johns Hopkins University. Recent studies have reported factors in association with
prolonged duration of viral RNA shedding [2, 3]. But so far, no study has demonstrated
the effects of antiviral drug administration on the duration of viral shedding and clinical
improvement in COVID-19 patients. We investigated the time of antiviral drug administration
in COVID-19 patients with factors and inhibitors associated with prolonged viral shedding,
clinical improvement and cytokine storm, respectively.
Copyright © 2020 by The Korean Society
of Infectious Diseases, Korean Society for
Antimicrobial Therapy, and The Korean Society
for AIDS
We..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit